Ipatasertib
Ipatasertib is an oral, highly selective pan-AKT inhibitor with a distinct chromenone scaffold developed by Genentech/Roche. It inhibits AKT1/2/3 with IC50 values in the low nanomolar range and shows particular activity in PTEN-deficient and PIK3CA-mutant models. Phase III trials (IPATunity130/150) have evaluated it in breast and prostate cancer; biomarker-selected patient populations show enhanced benefit.
Description
Scientific Overview: Ipatasertib is an oral, highly selective pan-AKT inhibitor with a distinct chromenone scaffold developed by Genentech/Roche. It inhibits AKT1/2/3 with IC50 values in the low nanomolar range and shows particular activity in PTEN-deficient and PIK3CA-mutant models. Phase III trials (IPATunity130/150) have evaluated it in breast and prostate cancer; biomarker-selected patient populations show enhanced benefit.
Mechanism of Action: Pan-AKT (AKT1/2/3) Inhibitor
Purity: ≥99% | Molecular Formula: C25H26FN5O3
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | Pan-AKT (AKT1/2/3) Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C25H26FN5O3 |
| CAS Number | 1001264-89-6 |
